Xiaobo Liu

Title: Innovations of Xiaobo Liu in Antibody Engineering

Introduction

Xiaobo Liu is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of antibody engineering, particularly in enhancing the efficacy of therapeutic antibodies. His innovative work focuses on the development of antibody heavy chain constant regions that improve agonistic activity, which is crucial for treating various diseases.

Latest Patents

Xiaobo Liu holds a patent titled "Sequence of antibody heavy chain constant region for enhancing agonistic antibody activity." This patent describes a heavy chain constant region that includes a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain. The sequences of the CH1 domain and hinge region are derived from human IgG2, while the CH2 and CH3 domains are based on human IgGs. The invention ensures that the antibody heavy chain constant region has an affinity to human FcγRIIB that is equal to or higher than that of human IgG1. This advancement significantly enhances the agonistic activity of antibodies or fusion proteins, improving their efficacy in treating tumors and autoimmune diseases. Xiaobo Liu has 1 patent to his name.

Career Highlights

Xiaobo Liu is affiliated with Shanghai Jiao Tong University, where he conducts research and develops innovative solutions in the field of biotechnology. His work has garnered attention for its potential impact on therapeutic applications, particularly in the treatment of complex diseases.

Collaborations

Xiaobo Liu collaborates with notable colleagues, including Fubin Li and Yan Zhang. Their combined expertise contributes to the advancement of research in antibody engineering and related fields.

Conclusion

Xiaobo Liu's contributions to antibody engineering exemplify the importance of innovation in medical science. His patented work enhances the therapeutic potential of antibodies, paving the way for improved treatments for various diseases.